Nisa Investment Advisors LLC Has $214,000 Stake in Organon & Co. $OGN

Nisa Investment Advisors LLC trimmed its holdings in Organon & Co. (NYSE:OGN) by 48.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,140 shares of the company’s stock after selling 20,587 shares during the period. Nisa Investment Advisors LLC’s holdings in Organon & Co. were worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ransom Advisory Ltd acquired a new position in Organon & Co. in the first quarter valued at about $32,000. Hanson & Doremus Investment Management acquired a new position in Organon & Co. in the second quarter valued at about $26,000. Brooklyn Investment Group grew its stake in Organon & Co. by 1,012.3% in the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after acquiring an additional 2,794 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Organon & Co. in the first quarter valued at about $51,000. Finally, PARK CIRCLE Co grew its stake in Organon & Co. by 640.7% in the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock valued at $60,000 after acquiring an additional 3,460 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OGN has been the topic of a number of research reports. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a report on Monday, October 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Organon & Co. currently has a consensus rating of “Hold” and an average price target of $13.00.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $6.70 on Tuesday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 2.49, a price-to-earnings-growth ratio of 0.61 and a beta of 0.63. The stock’s 50-day moving average is $9.61 and its 200-day moving average is $9.68. Organon & Co. has a one year low of $6.18 and a one year high of $18.02. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13.

Organon & Co. (NYSE:OGN) last released its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the prior year, the company posted $1.12 earnings per share. Organon & Co.’s revenue was down .8% on a year-over-year basis. Equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.